Preventing Respiratory Syncytial Virus (RSV)
RSV is the number one cause for hospitalization in babies less than one year old. But these hospitalizations can be easily prevented with monthly injections of SYNAGIS throughout the cold and flu season. SYNAGIS is the only prophylactic medication available on the market to help prevent this serious infection. Magellan/ICORE is a limited distribution provider of SYNAGIS and strongly supports its use to reduce risks of hospitalization of infants and young children.
To learn more about RSV and how common cold symptoms can lead to respiratory distress and hospitalization, especially in babies considered high-risk, read, Coldlike RSV threatens babies.
